{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T06:34:32Z","timestamp":1777185272366,"version":"3.51.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,25]]},"DOI":"10.7759\/cureus.107715","type":"journal-article","created":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:39:16Z","timestamp":1777181956000},"source":"Crossref","is-referenced-by-count":0,"title":["Semaglutide and Its Potential Hepatoprotective Effects Against Acute Drug-Induced Liver Injury"],"prefix":"10.7759","author":[{"given":"Eftychia","family":"Charatsi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Liberopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasilios","family":"Pergialiotis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Kontzoglou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Kykalos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Iliopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-016-0550-0","article-title":"The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study","volume":"16","author":"Sobhonslidsuk A","year":"2016","unstructured":"Sobhonslidsuk A, Poovorawan K, Soonthornworasiri N, Pan-Ngum W, Phaosawasdi K. The incidence, presentation, outcomes, risk of mortality and economic data of drug-induced liver injury from a national database in Thailand: a population-base study. BMC Gastroenterol. 2016, 16:135. 10.1186\/s12876-016-0550-0","journal-title":"BMC Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16146","article-title":"Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs","volume":"45","author":"Suzuki A","year":"2025","unstructured":"Suzuki A, MinjunChen. Epidemiology and risk determinants of drug-induced liver injury: current knowledge and future research needs. Liver Int. 2025, 45:e16146. 10.1111\/liv.16146","journal-title":"Liver Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02885-1","article-title":"Drug induced liver injury: an update","volume":"94","author":"Garcia-Cortes M","year":"2020","unstructured":"Garcia-Cortes M, Robles-Diaz M, Stephens C, Ortega-Alonso A, Lucena MI, Andrade RJ. Drug induced liver injury: an update. Arch Toxicol. 2020, 94:3381-407. 10.1007\/s00204-020-02885-1","journal-title":"Arch Toxicol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.98","article-title":"The natural history of severe acute liver injury","volume":"112","author":"Koch DG","year":"2017","unstructured":"Koch DG, Speiser JL, Durkalski V, et al.. The natural history of severe acute liver injury. Am J Gastroenterol. 2017, 112:1389-96. 10.1038\/ajg.2017.98","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/jpbs.jpbs_568_25","article-title":"Drug-induced liver injury: mechanisms, diagnosis, and management: a review","volume":"17","author":"Keshari AC","year":"2025","unstructured":"Keshari AC, Thitame SN, Aher AA, Keshari UC. Drug-induced liver injury: mechanisms, diagnosis, and management: a review. J Pharm Bioallied Sci. 2025, 17:S55-8. 10.4103\/jpbs.jpbs_568_25","journal-title":"J Pharm Bioallied Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70327","article-title":"DILI is an important cause of hepatocellular and mixed liver injury-a nationwide prospective study on elevated liver enzymes","volume":"45","author":"Sigurdarson SS","year":"2025","unstructured":"Sigurdarson SS, Bjornsson HK, Snorrason BL, Bjornsson ES. DILI is an important cause of hepatocellular and mixed liver injury-a nationwide prospective study on elevated liver enzymes. Liver Int. 2025, 45:e70327. 10.1111\/liv.70327","journal-title":"Liver Int"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2025.102635","article-title":"Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: assess the causal relationship using the updated RUCAM scale","volume":"49","author":"Wang P","year":"2025","unstructured":"Wang P, Guo G, Jiang S, et al.. Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: assess the causal relationship using the updated RUCAM scale. Clin Res Hepatol Gastroenterol. 2025, 49:102635. 10.1016\/j.clinre.2025.102635","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-025-05744-3","article-title":"Mechanisms of drug induced liver injury","volume":"82","author":"Skat-R\u00f8rdam J","year":"2025","unstructured":"Skat-R\u00f8rdam J, Lykkesfeldt J, Gluud LL, Tveden-Nyborg P. Mechanisms of drug induced liver injury. Cell Mol Life Sci. 2025, 82:213. 10.1007\/s00018-025-05744-3","journal-title":"Cell Mol Life Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10030390","article-title":"Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice","volume":"10","author":"Villanueva-Paz M","year":"2021","unstructured":"Villanueva-Paz M, Mor\u00e1n L, L\u00f3pez-Alc\u00e1ntara N, Freixo C, Andrade RJ, Lucena MI, Cubero FJ. Oxidative stress in drug-induced liver injury (DILI): from mechanisms to biomarkers for use in clinical practice. Antioxidants (Basel). 2021, 10:390. 10.3390\/antiox10030390","journal-title":"Antioxidants (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.104","article-title":"Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies","volume":"13","author":"Ju C","year":"2016","unstructured":"Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol. 2016, 13:316-27. 10.1038\/cmi.2015.104","journal-title":"Cell Mol Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29689","article-title":"New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases","volume":"67","author":"Win S","year":"2018","unstructured":"Win S, Than TA, Zhang J, Oo C, Min RW, Kaplowitz N. New insights into the role and mechanism of c-Jun-N-terminal kinase signaling in the pathobiology of liver diseases. Hepatology. 2018, 67:2013-24. 10.1002\/hep.29689","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04483.x","article-title":"Recent advances in incretin-based therapies","volume":"77","author":"Russell-Jones D","year":"2012","unstructured":"Russell-Jones D, Gough S. Recent advances in incretin-based therapies. Clin Endocrinol (Oxf). 2012, 77:489-99. 10.1111\/j.1365-2265.2012.04483.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker DJ","year":"2022","unstructured":"Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab. 2022, 57:101351. 10.1016\/j.molmet.2021.101351","journal-title":"Mol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-025-01663-z","article-title":"The expanding role of semaglutide: beyond glycemic control","volume":"24","author":"Zarei M","year":"2025","unstructured":"Zarei M, Sabetkasaei M, Mozafari M, Zaeri S. The expanding role of semaglutide: beyond glycemic control. J Diabetes Metab Disord. 2025, 24:160. 10.1007\/s40200-025-01663-z","journal-title":"J Diabetes Metab Disord"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.95632","article-title":"Semaglutide in metabolic dysfunction-associated steatohepatitis: a narrative review","volume":"17","author":"Zacharia GS","year":"2025","unstructured":"Zacharia GS, Gongati SR, Kharel A, Jacob A. Semaglutide in metabolic dysfunction-associated steatohepatitis: a narrative review. Cureus. 2025, 17:e95632. 10.7759\/cureus.95632","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3390\/ph18071075","article-title":"Semaglutide in MASLD patients: improved survival and liver outcomes","volume":"18","author":"Suki M","year":"2025","unstructured":"Suki M, Amer J, Milgrom Y, et al.. Semaglutide in MASLD patients: improved survival and liver outcomes. Pharmaceuticals (Basel). 2025, 18:1075. 10.3390\/ph18071075","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/medsci13040265","article-title":"Semaglutide from bench to bedside: the experimental journey towards a transformative therapy for diabetes, obesity and metabolic liver disorders","volume":"13","author":"Weiskirchen R","year":"2025","unstructured":"Weiskirchen R, Lonardo A. Semaglutide from bench to bedside: the experimental journey towards a transformative therapy for diabetes, obesity and metabolic liver disorders. Med Sci (Basel). 2025, 13:265. 10.3390\/medsci13040265","journal-title":"Med Sci (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70407","article-title":"Focus on semaglutide 2.4\u2009mg\/week for the treatment of metabolic dysfunction-associated steatohepatitis","volume":"45","author":"Petta S","year":"2025","unstructured":"Petta S, Kim K, Targher G, et al.. Focus on semaglutide 2.4\u2009mg\/week for the treatment of metabolic dysfunction-associated steatohepatitis. Liver Int. 2025, 45:e70407. 10.1111\/liv.70407","journal-title":"Liver Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-24. 10.1056\/NEJMoa2028395"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13037","article-title":"Semaglutide improves metabolic dysfunction-associated steatohepatitis: a 10-year retrospective study","volume":"8","author":"Shah P","year":"2024","unstructured":"Shah P, White M, Sievert A, et al.. Semaglutide improves metabolic dysfunction-associated steatohepatitis: a 10-year retrospective study. JGH Open. 2024, 8:e13037. 10.1002\/jgh3.13037","journal-title":"JGH Open"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15898","article-title":"Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study","volume":"26","author":"Arai T","year":"2024","unstructured":"Arai T, Atsukawa M, Tsubota A, et al.. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: a prospective, multicentre, observational study. Diabetes Obes Metab. 2024, 26:4958-65. 10.1111\/dom.15898","journal-title":"Diabetes Obes Metab"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81:492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1097\/01.JAA.0000000000000296","article-title":"Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"39","author":"Geary A","year":"2026","unstructured":"Geary A. Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD). JAAPA. 2026, 39:21-5. 10.1097\/01.JAA.0000000000000296","journal-title":"JAAPA"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg H","year":"2026","unstructured":"Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA. 2026, 335:163-74. 10.1001\/jama.2025.19615","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes. Diabetes Care. 2025, 48:S181-206. 10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut JM","year":"2023","unstructured":"Yabut JM, Drucker DJ. Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease. Endocr Rev. 2023, 44:14-32. 10.1210\/endrev\/bnac018","journal-title":"Endocr Rev"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-024-05507-6","article-title":"GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells","volume":"81","author":"da Silva Lima N","year":"2024","unstructured":"da Silva Lima N, Cabaleiro A, Novoa E, et al.. GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cells. Cell Mol Life Sci. 2024, 81:468. 10.1007\/s00018-024-05507-6","journal-title":"Cell Mol Life Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction-associated steatohepatitis","volume":"135","author":"Newsome PN","year":"2025","unstructured":"Newsome PN, Loomba R. Therapeutic horizons in metabolic dysfunction-associated steatohepatitis. J Clin Invest. 2025, 135:e186425. 10.1172\/JCI186425","journal-title":"J Clin Invest"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo S","year":"2011","unstructured":"Ben-Shlomo S, Zvibel I, Shnell M, et al.. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011, 54:1214-23. 10.1016\/j.jhep.2010.09.032","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13206100","article-title":"Semaglutide treatment effects on liver fat content in obese subjects with metabolic-associated steatotic liver disease (MASLD)","volume":"13","author":"Dusilov\u00e1 T","year":"2024","unstructured":"Dusilov\u00e1 T, Kov\u00e1\u0159 J, La\u0148kov\u00e1 I, et al.. Semaglutide treatment effects on liver fat content in obese subjects with metabolic-associated steatotic liver disease (MASLD). J Clin Med. 2024, 13:6100. 10.3390\/jcm13206100","journal-title":"J Clin Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta NA","year":"2010","unstructured":"Gupta NA, Mells J, Dunham RM, Grakoui A, Handy J, Saxena NK, Anania FA. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology. 2010, 51:1584-92. 10.1002\/hep.23569","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194751","article-title":"Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits","volume":"135","author":"Wong CK","year":"2025","unstructured":"Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025, 135:e194751. 10.1172\/JCI194751","journal-title":"J Clin Invest"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001776","article-title":"Semaglutide-induced liver injury","volume":"12","author":"Kalsi H","year":"2025","unstructured":"Kalsi H, Arora SS, Essilfie-Quaye K, Bassi R, Akhavan N, Perbtani Y, Brar TS. Semaglutide-induced liver injury. ACG Case Rep J. 2025, 12:e01776. 10.14309\/crj.0000000000001776","journal-title":"ACG Case Rep J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12833","article-title":"Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study","volume":"19","author":"Knapen LM","year":"2017","unstructured":"Knapen LM, de Jong RG, Driessen JH, et al.. Use of incretin agents and risk of acute and chronic pancreatitis: a population-based cohort study. Diabetes Obes Metab. 2017, 19:401-11. 10.1111\/dom.12833","journal-title":"Diabetes Obes Metab"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba R","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al.. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023, 8:511-22. 10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3390\/toxics13070594","article-title":"Liraglutide attenuates atorvastatin-induced hepatotoxicity by restoring GLP-1R expression and activating Nrf2 and autophagy pathways in Wistar rats","volume":"13","author":"Elsiad EA","year":"2025","unstructured":"Elsiad EA, Abd El Aal HA, Salem HA, El-Yamany MF, Rabie MA. Liraglutide attenuates atorvastatin-induced hepatotoxicity by restoring GLP-1R expression and activating Nrf2 and autophagy pathways in Wistar rats. Toxics. 2025, 13:594. 10.3390\/toxics13070594","journal-title":"Toxics"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.04.011","article-title":"The GLP-1 analog liraglutide attenuates acute liver injury in mice","volume":"18","author":"Milani L","year":"2019","unstructured":"Milani L, Galindo CM, Turin de Oliveira NM, et al.. The GLP-1 analog liraglutide attenuates acute liver injury in mice. Ann Hepatol. 2019, 18:918-28. 10.1016\/j.aohep.2019.04.011","journal-title":"Ann Hepatol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2019.04.160","article-title":"Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice","volume":"514","author":"Zhang WY","year":"2019","unstructured":"Zhang WY, Hu XF, Wan N, et al.. Protective effect of the glucagon-like peptide-1 analogue liraglutide on carbon tetrachloride-induced acute liver injury in mice. Biochem Biophys Res Commun. 2019, 514:386-92. 10.1016\/j.bbrc.2019.04.160","journal-title":"Biochem Biophys Res Commun"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.869050","article-title":"Liraglutide attenuates hepatic ischemia-reperfusion injury by modulating macrophage polarization","volume":"13","author":"Li SL","year":"2022","unstructured":"Li SL, Wang ZM, Xu C, et al.. Liraglutide attenuates hepatic ischemia-reperfusion injury by modulating macrophage polarization. Front Immunol. 2022, 13:869050. 10.3389\/fimmu.2022.869050","journal-title":"Front Immunol"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.4103\/1319-3767.65187","article-title":"Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide","volume":"16","author":"Vaghasiya JD","year":"2010","unstructured":"Vaghasiya JD, Sheth NR, Bhalodia YS, Jivani NP. Exaggerated liver injury induced by renal ischemia reperfusion in diabetes: effect of exenatide. Saudi J Gastroenterol. 2010, 16:174-80. 10.4103\/1319-3767.65187","journal-title":"Saudi J Gastroenterol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10122028","article-title":"Preventing oxidative stress in the liver: an opportunity for GLP-1 and\/or PASK","volume":"10","author":"Hurtado-Carneiro V","year":"2021","unstructured":"Hurtado-Carneiro V, Dongil P, P\u00e9rez-Garc\u00eda A, \u00c1lvarez E, Sanz C. Preventing oxidative stress in the liver: an opportunity for GLP-1 and\/or PASK. Antioxidants (Basel). 2021, 10:2028. 10.3390\/antiox10122028","journal-title":"Antioxidants (Basel)"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19010026","article-title":"Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling","volume":"19","author":"Oh YS","year":"2017","unstructured":"Oh YS, Jun HS. Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci. 2017, 19:26. 10.3390\/ijms19010026","journal-title":"Int J Mol Sci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.149","article-title":"Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway","volume":"510","author":"Li Z","year":"2019","unstructured":"Li Z, Feng PP, Zhao ZB, Zhu W, Gong JP, Du HM. Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway. Biochem Biophys Res Commun. 2019, 510:20-6. 10.1016\/j.bbrc.2018.12.149","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/477982-semaglutide-and-its-potential-hepatoprotective-effects-against-acute-drug-induced-liver-injury","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T05:39:17Z","timestamp":1777181957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/477982-semaglutide-and-its-potential-hepatoprotective-effects-against-acute-drug-induced-liver-injury"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.107715","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,25]]}}}